No | No atopic | No combined pill | Duration recurrent VVC (years) | Episodes subjective VVC in previous year | Episodes subjective VVC during treatment* | Episodes subjective VVC during treatment* (minus −ve swabs) | No swabs taken* | No positive swabs* | Improve-ment exit score | Take again exit score | Side effects exit score | No symptom free 1 year 3 months) post-treatment | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
*Rate adjusted to per 24 weeks for those exiting the study before 24 weeks. | |||||||||||||
†Does not include the patient remaining on zafirlukast (see text). | |||||||||||||
“Complete” responders | 6 | 2 | 1 | 7.6 (7) | 11.4 (12) | 0.8 (0) | 0.8 (0) | 1.6 (2) | 0.2 (0) | 10 (10) | 10 (10) | 1.5 (1) | 4 (6) |
“Non-complete” responders | 14 | 10 | 2 | 7.8 (4.5) | 12.8 (12) | 5.5 (5) | 5.5.1 (5) | 2.6 (2.5) | 2.0 (2) | 4.7 (6) | 5.5 (5.4) | 1 (1) | 3 (5)† |
Subjective responders | 14 | 9 | 2 | 8.1 (7.5) | 12.4 (10) | 2.6 (2) | 2.6 (2) | 1.8 (2) | 1 (0.93) | 8.4 (8) | 9.1 (10) | 1.5 (1) | 7 (11)† |
Subjective non-responders | 6 | 3 | 1 | 6.9 (2.8) | 12.3 (12) | 7.9 (6) | 7.9 (6) | 3.9 (4) | 3.9 (4) | 1.7 (1.5) | 1.3 (1) | 1 (1) | 0 (0) |